Farshad Mirzavi

Farshad Mirzavi

Auto-generated profile, based on publicly available information

Farshad Mirzavi

Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2021 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
MBMehdi Barati
Mehdi Barati
FMFarshad Mirzavi
Farshad Mirzavi
ANAmin Reza Nikpoor
Amin Reza Nikpoor
MSMojtaba Sankian
Mojtaba Sankian
HAHasan Namdar Ahmadabad
Hasan Namdar Ahmadabad
MJMahmoud Reza Jaafari
Mahmoud Reza Jaafari

28 August 2023 in Journal of Nanoparticle Research
Verified
Journal Article
Closed access
PDF file
ZNZohreh Najafi
Zohreh Najafi
EEElham Einafshar
Elham Einafshar
FMFarshad Mirzavi
Farshad Mirzavi
HAHamed Amiri
Hamed Amiri
MJMohammad Jalili-nik
Mohammad Jalili-nik
MSMohammad Soukhtanloo
Mohammad Soukhtanloo

22 December 2022 in Alternatives to Laboratory Animals
Verified
Journal Article
Closed access
FAFarzaneh Abbasinezhad-Moud
Farzaneh Abbasinezhad-Moud
FMFarshad Mirzavi
Farshad Mirzavi
HRHassan Rakhshandeh
Hassan Rakhshandeh
RMReza Mohebbati
Reza Mohebbati
FFFatemeh Forouzanfar
Fatemeh Forouzanfar
MSMohammad Soukhtanloo
Mohammad Soukhtanloo
The pathological accumulation of quinolinic acid (QA) is often associated with neuritis and neuronal cell death in several neurodegenerative diseases, through the overproduction of free radicals. Urolithin B and auraptene have been reported to exert potent antioxidant effects — however, little is known about the protective effects of these compounds against QA-induced neurotoxicity. Therefore, this study aimed to explore the in vitro protective effects of urolithin B and auraptene against QA-induced neurotoxicity in the SH-SY5Y neuroblastoma cell line. The MTT assay was used to evaluate cell viability, and flow cytometry was carried out to evaluate effects on the cell cycle and apoptosis. The intracellular levels of reactive oxygen species (ROS) were also determined. Our findings showed that auraptene at non-toxic concentrations had no protective effect on QA-induced toxicity. However, urolithin B at concentrations of 0.6 μM and 2.5 μM enhanced the viability of cells treated with QA. Moreover, while the percentage of apoptotic cells (i.e. in the sub-G1 phase) was shown to significantly increase after QA treatment, pre-treatment with urolithin B reduced the number of these apoptotic cells. Furthermore, urolithin B, as an antioxidant, also significantly reduced QA-induced ROS production. Our findings suggest that urolithin B may possess potent antioxidant and neuroprotective effects against QA-induced neurotoxicity that merit further investigation.

24 August 2022 in Biologia
Verified
Journal Article
Closed access
PDF file
HSHossein Saghi
Hossein Saghi
FMFarshad Mirzavi
Farshad Mirzavi
AAAmir R. Afshari
Amir R. Afshari
MJMohammad Jalili-nik
Mohammad Jalili-nik
BMBaratali Mashkani
Baratali Mashkani
MSMohammad Soukhtanloo
Mohammad Soukhtanloo

13 August 2023 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Closed access
PDF file
AIAzam Izadi
Azam Izadi
ASAsie Sadeghi
Asie Sadeghi
MJMohammad Jalili-nik
Mohammad Jalili-nik
FMFarshad Mirzavi
Farshad Mirzavi
AAAmir R. Afshari
Amir R. Afshari
MSMohammad Soukhtanloo
Mohammad Soukhtanloo

12 November 2025 in BioFactors
Verified
Journal Article
Closed access
ATAzadeh Taherpour
Azadeh Taherpour
SESafieh Ebrahimi
Safieh Ebrahimi
FMFarshad Mirzavi
Farshad Mirzavi